ライフサイエンスコーパス: dopamine transporter

1 still reinforcing even in the absence of the dopamine transporter.

2 ear accumbens without affecting the level of dopamine transporter.

3 ompete with (123)I-FP-CIT for binding to the dopamine transporter.

4 n the transport of AMPH into the cell by the dopamine transporter.

5 ropyl]piperazine), a specific blocker of the dopamine transporter.

6 increases synaptic dopamine by blocking the dopamine transporter.

7 isorder caused by genetic alterations of the dopamine transporter.

8 o cholesterol/CHS in Drosophila melanogaster dopamine transporter.

9 smitter-sodium symporters, such as the human dopamine transporter.

10 ase (COMT), but negligible expression of the dopamine transporter.

11 se of dopamine through reverse activation of dopamine transporters.

12 xcellent selectivity over both serotonin and dopamine transporters.

13 rine transporter over both the serotonin and dopamine transporters.

14 iors by regulating the level and function of dopamine transporters.

15 both total and synaptic membrane-associated dopamine transporters.

16 amics simulations of a complete model of the dopamine transporter, a NSS protein, we observed a parti

17 Striatal dopamine transporter abnormalities are thought to underl

18 asurement of functional parameters including dopamine transporter activity and dopamine release at th

19 n one patient, which showed complete loss of dopamine transporter activity in the basal nuclei.

20 in this cohort suggests that higher residual dopamine transporter activity is likely to contribute to

21 Class II ligands, including the dopamine transporter, adopt a canonical binding mode wit

22 ase (TH), vesicular monoamine transporter 2, dopamine transporter and aldehyde dehydrogenase 1.

23 de dynamic PET scans were performed to image dopamine transporter and D(2)-like receptors, respective

24 imarily regulate striatal dopamine function--dopamine transporter and D2 receptors--was significantly

25 in the striatum, as well as altered striatal dopamine transporter and D2, but not D1, receptor densit

26 and to relate findings to juvenile levels of dopamine transporter and D2-like receptor availabilities

27 models based on the Drosophila melanogaster dopamine transporter and docked paroxetine to these mode

28 ased in direct proportion to declines in the dopamine transporter and dopamine uptake.

29 o those of presynaptic function and those of dopamine transporter and receptor availability.

30 show that betaPEA, like Amph, activates the dopamine transporter and the amine-gated chloride channe

31 The tetracyclic compound inhibits both the dopamine transporter and the serotonin transporter, and

32 cient animals in striatal dopamine levels or dopamine transporter and tyrosine hydroxylase expression

33 s well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreac

34 appears to be consistently smaller than the dopamine transporter and vesicular monoamine transporter

35 ulant drug used to treat ADHD), which blocks dopamine transporters and norepinephrine transporters, a

36 the expression of the dopamine D2 receptor, dopamine transporter, and adenosine A1 receptor and decr

37 ne uptake, increases dopamine efflux via the dopamine transporter, and affects the excitability of do

38 re scanned with PET tracers for the membrane dopamine transporter, and dopamine synthesis and storage

39 nding phenylalanines 75 and 155 in the human dopamine transporter are the primary determinants of maz

40 tal structure of the Drosophila melanogaster dopamine transporter at 3.0 A resolution bound to the tr

41 dynorphin in situ hybridizations as well as dopamine transporter autoradiography.

42 e changes in dopamine D(2)/D(3) receptor and dopamine transporter availability (measured by changes i

43 Upregulation of dopamine transporter availability during long-term treat

44 methylphenidate treatment increased striatal dopamine transporter availability in ADHD (caudate, puta

45 he discrepancies in the literature regarding dopamine transporter availability in ADHD participants (

46 ability prior to treatment but showed higher dopamine transporter availability in ADHD participants t

47 dopamine transporter radioligand) to measure dopamine transporter availability in the brains of 18 ne

48 ipants revealed no significant difference in dopamine transporter availability prior to treatment but

49 Dopamine transporter availability was quantified as non-

50 icantly correlated with juvenile measures of dopamine transporter availability, whereas no significan

51 There was no evidence of alterations in dopamine transporter availability.

52 ed significant group differences in striatal dopamine transporter binding (all age ranges in caudate

53 kinson's disease (n=15) had reduced striatal dopamine transporter binding and (18)F-FDOPA uptake, com

54 Furthermore, these mice showed reduced dopamine transporter binding and slower dopamine clearan

55 )F-FDOPA uptake comparable with controls and dopamine transporter binding lower than in controls.

56 se (n=25) had greater (18)F-FDOPA uptake and dopamine transporter binding than did individuals with s

57 Striatal dopamine transporter binding, VMAT2 binding, (18)F-FDOPA

58 In a neuroimaging substudy, striatal dopamine-transporter binding was assessed by SPECT.

59 al subregions, whereas both fluoxetine and a dopamine transporter blocker depress reuptake in striatu

60 Blockade of the dopamine transporter, but not the norepinephrine transpo

61 The dopamine transporter carries an endogenous binding site

62 lar monoamine transporter type 2 (DTBZ), and dopamine transporter (CFT) within 2 months after nigrost

63 Together, the data suggest that the dopamine transporter contributes to homeostatic sleep-wa

64 h genes in postmitotic mDA neurons using the dopamine transporter-cre mouse.

65 PDM blocked the endogenous basal hDAT (human dopamine transporter) current in voltage-clamped (-60 mV

66 pamine activity is normally regulated by the dopamine transporter (DAT) and catechol-O-methyltransfer

67 nterval timing in mice that underexpress the dopamine transporter (DAT) and have chronically higher l

68 l lines expressing the human plasma membrane dopamine transporter (DAT) and human VMAT ortholog, VMAT

69 ized, and evaluated for binding at the SERT, dopamine transporter (DAT) and norepinephrine transporte

70 anges using Western immunoblotting [striatal dopamine transporter (DAT) and tyrosine hydroxylase (TH)

71 cle deacidification also requires functional dopamine transporter (DAT) at the plasma membrane.

72 addition, PET was used to examine changes in dopamine transporter (DAT) availability after social hie

73 DG PET provides complementary information on dopamine transporter (DAT) availability and overall brai

74 Dopamine D(2)-like receptor and dopamine transporter (DAT) availability and reversal-lea

75 lucinations, and fluctuations) with striatal dopamine transporter (DAT) availability as assessed with

76 We also measured dopamine transporter (DAT) availability in three subject

77 Dopamine transporter (DAT) availability was assessed wit

78 The dopamine transporter (DAT) belongs to the family of neur

79 The dopamine transporter (DAT) belongs to the neurotransmitt

80 g pregnancy, we imaged striatal and midbrain dopamine transporter (DAT) binding by positron emission

81 We compared the striatal dopamine transporter (DAT) binding in FTD (n=12), DLB (n

82 reduces Parkinsonian symptoms and increases dopamine transporter (DAT) binding in several animal mod

83 tudy was to examine the relationship between dopamine transporter (DAT) binding in the striatum in in

84 T) SPECT can visualize and quantify striatal dopamine transporter (DAT) binding in vivo.

85 related human alpha-synuclein A53T mutant or dopamine transporter (DAT) blockers also differentially

86 Folding-defective mutants of the human dopamine transporter (DAT) cause a syndrome of infantile

87 The dopamine transporter (DAT) clears the extracellular dopa

88 The sodium-coupled dopamine transporter (DAT) controls dopamine homeostasis

89 The dopamine transporter (DAT) controls the spatial and temp

90 yrosine hydroxylase (TH) immunohistology and dopamine transporter (DAT) density with DAT immunohistol

91 puted tomography (SPECT), to assess striatal dopamine transporter (DAT) density.

92 que dopamine uptake inhibitor that binds the dopamine transporter (DAT) differently than cocaine and

93 ple aspects of dopamine signaling, including dopamine transporter (DAT) expression and dopamine reupt

94 anes 9-12 were synthesized as ligands of the dopamine transporter (DAT) for use as (18)F-labeled posi

95 in an enriched condition (EC) have decreased dopamine transporter (DAT) function and expression in me

96 Dopamine transporter (DAT) function is altered by many n

97 cit are unknown, but may include the reduced dopamine transporter (DAT) functioning reported in BD pa

98 The dopamine transporter (DAT) functions as a key regulator

99 rder caused by loss-of-function mutations in dopamine transporter (DAT) gene, leading to severe neuro

100 The human dopamine transporter (DAT) has a tetrahedral Zn(2+)-bind

101 ed transport reversal at the closely related dopamine transporter (DAT) has been shown previously to

102 Dopamine transporter (DAT) has been shown to accumulate

103 of smell identification testing followed by dopamine transporter (DAT) imaging can accurately and ef

104 To determine the usefulness of dopamine transporter (DAT) imaging to identify idiopathi

105 e top candidate biomarker were measured, and dopamine transporter (DAT) imaging was performed, to eva

106 ere used to measure cocaine occupancy of the dopamine transporter (DAT) in nonhuman primates.

107 de antisera against M5R and the plasmalemmal dopamine transporter (DAT) in single sections through th

108 ligand for the in vivo quantification of the dopamine transporter (DAT) in the striatum and substanti

109 effects on [DA]o at high and low doses, one dopamine transporter (DAT) independent and one DAT depen

110 ry for ubiquitination and endocytosis of the dopamine transporter (DAT) induced by the activation of

111 The dopamine transporter (DAT) inhibitor, nomifensine, simil

112 The dopamine transporter (DAT) is a crucial regulator of dop

113 The dopamine transporter (DAT) is a major regulator of synap

114 The dopamine transporter (DAT) is a presynaptic membrane pro

115 The dopamine transporter (DAT) is an important regulator of

116 The neuronal plasma membrane dopamine transporter (DAT) is essential for the maintena

117 The dopamine transporter (DAT) is responsible for sequestrat

118 The dopamine transporter (DAT) is responsible for terminatin

119 The dopamine transporter (DAT) is the key regulator of the d

120 The dopamine transporter (DAT) is the primary molecular targ

121 The dopamine transporter (DAT) is the primary site of action

122 Although the dopamine transporter (DAT) is the primary site of action

123 Dopamine transporter (DAT) is the target of cocaine and

124 oltammetry in rats, as well as wild-type and dopamine transporter (DAT) knock-out mice, we demonstrat

125 at MPH self-administration in rats increases dopamine transporter (DAT) levels and enhances the poten

126 te of uptake (Vmax), and membrane-associated dopamine transporter (DAT) levels were reduced, and the

127 mission and mania, whilst increased striatal dopamine transporter (DAT) levels would lead to reduced

128 ures reminiscent of ADHD, including elevated dopamine transporter (DAT) levels, hyperactivity, workin

129 asis on SPECT performed with the presynaptic dopamine transporter (DAT) ligand (123)I-FP-CIT.

130 sion of rat SNCA, tyrosine hydroxylase (TH), dopamine transporter (DAT) or the vesicular monoamine tr

131 tropane ((18)F-FE-PE2I) is a newly developed dopamine transporter (DAT) PET radioligand.

132 As an approach to elucidating dopamine transporter (DAT) phosphorylation characteristi

133 As the dopamine transporter (DAT) plays a prominent role in the

134 Taking advantage of a dopamine transporter (DAT) promoter-driven tetracycline

135 t binds reversibly with high affinity to the dopamine transporter (DaT) protein, a marker for presyna

136 The dopamine transporter (DAT) regulates dopamine (DA) neuro

137 ynamic membrane trafficking of the monoamine dopamine transporter (DAT) regulates dopaminergic signal

138 Uptake through the dopamine transporter (DAT) represents the primary mechan

139 The dopamine transporter (DAT) reversibly transports dopamin

140 The plasma membrane dopamine transporter (DAT) takes extracellular dopamine

141 ives post translational modifications at the dopamine transporter (DAT) to increase the ability of co

142 A53T mice had increased distribution of the dopamine transporter (DAT) to the membrane that was asso

143 uptake and [(3)H]WIN 35428 binding in human dopamine transporter (DAT) wild-type and mutants with al

144 we link tolerance to cocaine effects at the dopamine transporter (DAT) with aberrant cocaine-taking

145 It is targeting the dopamine transporter (DAT) with moderate selectivity, th

146 ed dopamine is regulated by the plasmalemmal dopamine transporter (DAT), an integral membrane protein

147 l terminals expressing TH, the high affinity dopamine transporter (DAT), and the vesicular monoamine

148 pamine transients are slower, independent of dopamine transporter (DAT), increasing the lifetime of e

149 can be identified by their expression of the dopamine transporter (DAT), provide the earliest opportu

150 In the human dopamine transporter (DAT), the corresponding residues a

151 ch as amphetamine and methamphetamine is the dopamine transporter (DAT), the major regulator of extra

152 on extracellular DA-level regulation by the dopamine transporter (DAT), the membrane expression and

153 ic re-uptake of dopamine is dependent on the dopamine transporter (DAT), which is regulated by its di

154 recessive loss-of-function mutations in the dopamine transporter (DAT), which often affects transpor

155 The dopamine transporter (DAT), which primarily sorts to deg

156 ction, and reduces cocaine inhibition of the dopamine transporter (DAT), which results in tolerance.

157 ryogenesis (EIIa-Cre) or only in DA neurons (dopamine transporter (DAT)-Cre), we developed constituti

158 In contrast to the classical dopamine transporter (DAT)-dependent enhancement of the

159 Striatal CYAM overlapped with the dopamine transporter (DAT).

160 the dopaminergic signal is regulated by the dopamine transporter (DAT).

161 the dopaminergic signal are regulated by the dopamine transporter (DAT).

162 morphism of the gene (DAT1, SLC6A3) encoding dopamine transporter (DAT).

163 ed transport by both SERT and the homologous dopamine transporter (DAT).

164 re controlled primarily by the action of the dopamine transporter (DAT).

165 fflux than [(3)H]dopamine uptake through the dopamine transporter (DAT).

166 imulant methamphetamine, a substrate for the dopamine transporter (DAT).

167 s of cocaine at its main site of action, the dopamine transporter (DAT).

168 rd relevant mechanistic targets, such as the dopamine transporter (DAT).

169 s, vesicular release of DA is cleared by the dopamine transporter (DAT).

170 stimulate endocytosis of the plasma membrane dopamine transporter (DAT).

171 hat individuals with genetic variants in the dopamine transporter (DAT, SLC6A) have a higher PD risk

172 ed a quantitative autoradiographic survey of dopamine transporter (DAT; [(3)H]mazindol), D1 receptor

173 mulation, and (2) DA reuptake occurs through dopamine transporters (DAT) in a manner consistent with

174 l data, APOE status, and biomarkers (CSF and dopamine transporter [DAT] imaging results).

175 -biotinyl exchange that native and expressed dopamine transporters (DATs) are palmitoylated, and usin

176 ht to result from cocaine's ability to block dopamine transporters (DATs).

177 binding availability of D2/D3 receptors and dopamine transporters (DATs).

178 al structures of the Drosophila melanogaster dopamine transporter (dDAT) bound to its substrate dopam

179 Dopamine Transporter Deficiency Syndrome (DTDS) is a rar

180 amine transporter gene, including hereditary dopamine transporter deficiency syndrome (DTDS).

181 expands the clinical phenotypic continuum of dopamine transporter deficiency syndrome and indicates t

182 Dopamine transporter deficiency syndrome due to SLC6A3 m

183 dopamine transporter deficiency syndrome is a newly reco

184 dopamine transporter deficiency syndrome is the first id

185 ncluded three adolescent males with atypical dopamine transporter deficiency syndrome of juvenile ons

186 Dopamine transporter deficiency syndrome remains under-r

187 nder-recognized and our data highlights that dopamine transporter deficiency syndrome should be consi

188 ren with a biochemical profile suggestive of dopamine transporter deficiency syndrome were enrolled f

189 a neurotransmitter profile characteristic of dopamine transporter deficiency syndrome were recruited

190 ave identified a new cohort of patients with dopamine transporter deficiency syndrome, including, mos

191 w patients from five unrelated families with dopamine transporter deficiency syndrome.

192 In vitro studies of mutant dopamine transporter demonstrated multifaceted loss of d

193 amine concentrations and decreased levels of dopamine transporter density along with increased brain-

194 n with serum urate level to predict striatal dopamine transporter density among all PPMI participants

195 individuals with physiological reductions in dopamine transporter density consistent with prodromal P

196 Striatal dopamine transporter density in ADHD appears to depend o

197 SPECT and PET studies investigating striatal dopamine transporter density in ADHD patients (N=169) an

198 the PPMI sample, on progression of striatal dopamine transporter density over the 22-month follow-up

199 Striatal dopamine transporter density was 14% higher on average i

200 son's disease and correlated the findings to dopamine transporter density, measured by (123)I-FP-CIT

201 Independent of striatal dopamine transporter density, similar effects on brain a

202 chostimulants was negatively correlated with dopamine transporter density; density was higher in pati

203 In contrast to NET, the dopamine transporter displayed markedly less constitutiv

204 neurochemical (ie, developmental changes in dopamine transporter, dopamine D(2) receptor density, an

205 (a drug that increases dopamine by blocking dopamine transporters) during sleep deprivation versus r

206 ice show comparable tyrosine hydroxylase and dopamine transporter expression in the embryonic and adu

207 ydroxylase (pTH-Ser40) levels in the VTA and dopamine transporter expression in the NAc.

208 lular side toward the unoccupied Na2 site of dopamine transporter following the release of the Na2-bo

209 Dopamine transporter function is regulated by protein ki

210 egenerative diseases that involve changes in dopamine transporter function.

211 ransporter demonstrated multifaceted loss of dopamine transporter function.

212 somal recessive disorder related to impaired dopamine transporter function.

213 In the dog, the dopamine transporter gene (DAT) contains a 38-base pair

214 n which Cre- recombinase expression is under dopamine transporter gene (DAT) promoter control to abla

215 Functional polymorphisms in the dopamine transporter gene (DAT1 or SLC6A3) modulate resp

216 ble number tandem repeat polymorphism in the dopamine transporter gene (DAT1/SLC6A3), which has been

217 unctional tandem repeat polymorphisms of the dopamine transporter gene (DAT1; SLC6A3), which are argu

218 We show that disruption of the dopamine transporter gene lengthens the period of ultrad

219 ditions have been linked to mutations in the dopamine transporter gene, including hereditary dopamine

220 opamine receptors, tyrosine hydroxylase, and dopamine transporter genes in the zebrafish brain.

221 face transporter, loss of post-translational dopamine transporter glycosylation and failure of amphet

222 imental verifications in both LeuT and human dopamine transporter (hDAT), we apply the novel method t

223 nsmission including dopamine uptake by human dopamine transporter (hDAT).

224 int mutations in the gene encoding the human dopamine transporter (hDAT, SLC6A3) cause a syndrome of

225 between occupancy and plasma concentration, dopamine transporter IC(50) (the plasma concentration of

226 line and assessed annually, including serial dopamine transporter imaging (DAT-SPECT) and ICD assessm

227 nt with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem

228 Other potential uses of dopamine transporter imaging include identification of p

229 ich to assess sensitivity and specificity of dopamine transporter imaging is a limitation, but defini

230 Dopamine transporter imaging was abnormal in all parkins

231 Brain perfusion and dopamine transporter imaging was analyzed, including dem

232 cluded cerebrospinal fluid (CSF) markers and dopamine transporter imaging.

233 disease who had undergone both diffusion and dopamine transporter imaging.

234 were processed for tyrosine hydroxylase and dopamine transporter immunohistochemistry.

235 that cocaine self-administration leaves the dopamine transporter in a "primed" state, which allows f

236 clinical decision making by visualising the dopamine transporter in parkinsonian cases.

237 123)I-FP-CIT) is commonly used to assess the dopamine transporter in the striatum.

238 While (123)I-FP-CIT binds primarily to dopamine transporters in the striatum, its binding in th

239 D(3)(-/-) mice also display up-regulation of dopamine transporters in the striatum, suggesting a neur

240 important role in regulating the function of dopamine transporters in the striatum.SIGNIFICANCE STATE

241 molecular dynamics trajectories of the human dopamine transporter, in which multiple spontaneous Na(+

242 nistration in rats produced tolerance to the dopamine transporter-inhibiting effects of cocaine in th

243 Strikingly, dopamine transporter inhibition completely restored alco

244 n of methylphenidate, as well as a selective dopamine transporter inhibitor, facilitated learning-ind

245 rupt D4 receptor activation initiated by the dopamine transporter inhibitor, GBR12935.

246 etamine (AMPH), cocaine, and other addictive dopamine-transporter inhibitors (DAT-Is) supports transi

247 The dopamine transporter is a neuronal protein that drives t

248 Although the overall structure of the dopamine transporter is similar to that of its prokaryot

249 hetamine enters dopamine neurons through the dopamine transporter, it stimulates endocytosis of an ex

250 me amphetamine-mediated behaviors persist in dopamine transporter knock-out animals, suggesting the e

251 s the spontaneous hyperactivity exhibited by dopamine transporter knock-out mice.

252 The dopamine transporter knockout (DAT KO) mouse is a model

253 ximately 80% decrease in brain serotonin and dopamine transporter knockout (DAT-KO) mice showing a fi

254 ar depression imaging studies show increased dopamine transporter levels, but changes in other aspect

255 nt results, i.e., both high and low striatal dopamine transporter levels.

256 tremor disorders, baseline imaging with the dopamine transporter ligand [(123)I]ioflupane (DaTscan)

257 nsients, suggesting that the activity of the dopamine transporter limits the detection of these event

258 in the NAc, whereas tyrosine hydroxylase and dopamine transporter mRNA levels and tissue dopamine con

259 Dopamine transporter mutants also showed diminished dopa

260 sally present, and more severely impacted in dopamine transporter mutants causing infantile-onset rat

261 profiling of rationally chosen serotonin and dopamine transporter mutants with respect to a series of

262 ically reduced in early stage, untreated and dopamine transporter neuroimaging-supported Parkinson's

263 ancy) was determined (4.5 ng/mL) and maximum dopamine transporter occupancy was extrapolated (85%); h

264 valuated by determining the effect of mutant dopamine transporter on dopamine uptake, protein express

265 recombinase under the control of either the dopamine transporter or the engrailed-1 promoters, we ge

266 he human serotonin transporter Tyr175 versus dopamine transporter Phe155 is found to be a strong tool

267 rol of the tyrosine hydroxylase, but not the dopamine transporter, promoter exhibit dramatic non-DA c

268 measurement of the binding potential of the dopamine transporter radioligand (123)I-ioflupane in mou

269 tron emission tomography and [(11)C]cocaine (dopamine transporter radioligand) to measure dopamine tr

270 arkinsonism had reduced dopamine storage and dopamine transporter reuptake.

271 ding the molecular determinants of serotonin/dopamine transporter selectivity and for the development

272 h PTE and genetic susceptibilities including dopamine transporter, serotonergic synaptic function, an

273 nes and barbiturates), and interactions with dopamine transporter, serotonin transporter, and vesicul

274 isms in the genes encoding the serotonin and dopamine transporters (SERT: 5HTTLPR plus rs25531; DAT1

275 The dopamine transporter shapes dopaminergic neurotransmissi

276 ss was smaller than the decrease in striatal dopamine transporter signal measured by dopamine transpo

277 (123)I-FP-CIT scan, the mean total striatal dopamine transporter signal was decreased by 45% and the

278 atal dopamine transporter signal measured by dopamine transporter single photon emission computed tom

279 d loss of dopaminergic neurons assessed with dopamine transporter single photon emission computerized

280 rend was found for the carriers allele 9R of dopamine transporter SLC6A3 40 bp variable tandem repeat

281 genes for dopamine beta-hydroxylase and the dopamine transporter SLC6A3 may play a role in migraine

282 dren with mutations in the gene encoding the dopamine transporter (SLC6A3) with the aim to improve cl

283 In mice with a dopamine transporter (Slc6a3)-driven conditional heteroz

284 Taken together, the dopamine transporter structure reveals the molecular bas

285 paminergic subpopulation using a fluorescent dopamine transporter substrate (ASP(+) [4-(4-diethylamin

286 sponsive FFN probe, FFN102, which as a polar dopamine transporter substrate selectively labels dopami

287 zation, insolubility and complexing with the dopamine transporter, suggesting a physiological mechani

288 nding residue found in the noradrenaline and dopamine transporters, switched the SEC24 isoform prefer

289 ethamphetamine (METH) is a substrate for the dopamine transporter that increases extracellular dopami

290 receptors, an increased translocation of the dopamine transporter to the plasma membrane and a corres

291 SPECT) with technetium 99m ((99m)Tc) tropane dopamine transporter (TRODAT)-1 were performed for furth

292 ed high levels of DOPA decarboxylase and the dopamine transporter, two markers expressed by fully mat

293 Imaging of the dopamine transporter using single-photon emission comput

294 , we separated isolated synaptosomes bearing dopamine transporters using immunomagnetic beads and com

295 trast, ubiquitination and endocytosis of the dopamine transporter was dependent on NEDD4-2 in all cel

296 ptor (MOR), preproenkephalin (PENK), and the dopamine transporter was evaluated in the hypothalamus a

297 At the doses evaluated, occupancy of the dopamine transporter was significantly higher than that

298 nal consequences of missense variants on the dopamine transporter were evaluated by determining the e

299 Mutant constructs of human dopamine transporter were used for in-vitro functional a

300 is essential for dopamine synthesis, and the dopamine transporter, which is required for dopamine upt